CCHFVaccine, initially planned as a six-year project launched in January 2017 and coordinated by Folkhälsomyndigheten (the Public Institute of Sweden, FoHM, Professor Ali Mirazimi) in Sweden, has now been extended to eight years.

This extension aims to ensure the successful launch of a phase 1 trial in humans. Consequently, the project end date is now set for December 2024.

It's worth noting that there is already confirmation of a continuation project, known as CCHFVACIM.

The CCHFVaccine project, has been built on the success of the CCH Fever project (FP7), which had focused on improving the knowledge of CCHFV, in general.

The specific aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) disease on a global basis.